Antiarrhythmic and antihypertensive activity of some xanthone derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 65, Issue 3, 2008, Pages 383-390

  Marona, Henryk ^a   Librowski, Tadeusz ^b   Cegła, Marek ^b   Erdoǧan, Cankat ^c   Şahin, Nefise Özlen ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c MERSIN UNIVERSITY   (Turkey)

Author keywords

Antiarrhythmic activity; Arterial blood pressure; Xanthone derivatives

Indexed keywords

1 [4 (BENZYL) 1 (PIPERAZINYL)] 3 (4 XANTHOXY) 2 PROPANOL; 1 [4 (ETHOXYCARBONYL) 1 (PIPERAZINYL)] 3 [4 XANTHONOXY) 2 PROPANOL; 1 [4 (HYDROXYETHYL) 1 (PIPERAZINYL)] 3 (4 XANTHONOXY) 2 PROPANOL; ADRENALIN; BARIUM CHLORIDE; CALCIUM CHLORIDE; PENTETRAZOLE; PROPRANOLOL; QUINIDINE; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRIC SHOCK; EXTRASYSTOLE; HEART ARRHYTHMIA; HEART RATE; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; QRS COMPLEX; QT INTERVAL; SEIZURE THRESHOLD;

ACUTE TOXICITY TESTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; GUINEA PIGS; HEART RATE; HYPERTENSION; MALE; MICE; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHONES;

EID: 45849097925     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chung M.I., Weng J.R., Wang J.P., Teng C.M., Lin C.N.: Planta Med. 68, 25 (2002).
2. Da Re P., Sagramora L., Mancini V., Valenti P., Cima L.: J. Med. Chem. 13, 527 (1970).
3. Dar A., Faizi S., Naqvi S., Roome T., Zikr-ur-Rehman S., Ali M., Firdous S., Moin S.T.: Biol. Pharm. Bull. 28, 596 (2005).
4. Ibrom W.G., Frahm A.W.: Arzneim.-Forsch./Drug Res. 47, 662 (1997).
5. Jastrzȩbska-Wiȩsek M., Librowski T., Czarnecki R., Marona H., Nowak G.: Pol. J. Pharmacol. 55, 461 (2003).
6. Lin C.N., Liou S.S., Ko F.N., Teng C.M.: J. Pharm. Sci. 82, 11 (1993).
7. Pfister J.R., Ferraresi R.W., Harrison I.T., Rooks W.H., Roszkowski A.P., Van Horn A., Fried J.H.: J. Med. Chem. 15, 1032 (1972).
8. Rewcastle G.W., Atwell G.J., Baguley B.C., Calveley S.B., Denny W.A.: J. Med. Chem. 32, 793 (1989).
9. Salmoiraghi I., Rossi M., Valenti P., Da Re P.: Arch. Pharm. (Weinheim) 331, 225 (1998).
10. Chen I.J., Liou S.J., Liou S.S., Lin C.N.: Gen. Pharmacol. 24, 1425 (1993).
11. Librowski, T., Czarnecki,, R., Jastrzȩbska, M. : Acta Pol. Pharm. Drug Res. 56, 87 (1999).
12. Marona H., Górka Z., Szneler E.: Pharmazie 53, 219 (1998).
13. Marona H., Szneler E., Filipek B., Sapa J.: Acta Pol. Pharm. Drug Res. 54, 63 (1997).
14. Marona H., Pȩkala E., Filipek B., Macia̧g D., Szneler E.: Pharmazie 56, 567 (2001).
15. Marona H., Czarnecki R., Librowski T., Woroń J.: Synthesis and influence of some 4-xanthon-oxypropanoloamine on circulatory system. XL Congress of Polish Chemical Society and Polish Association of Chemical Engineers, Gdańsk, 22-26 September, 1997.
16. Marona H., Szkaradek N., Kubacka M., Bednarski M., Filipek B., Cegła M., Szneler E.: Arch. Pharm. Chem. Life Sci. (2008, in press).
17. European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. Council of Europe, Strasbourg, 1983.
18. Deichmann W.B., Le Blanc T.J.: J. Ind. Hyg. Toxicol. 25, 415 (1943)
19. Litchfield J.T., Wilcoxon F.: J. Pharmacol. Exp. Ther. 96, 99 (1949).
20. Szekeres L., Papp J.G., in: Schimer J., Eichler O. (Eds.): Handbook of Experimental Pharmacology, pp. 131-182, Springer, Berlin, Heidelberg, New York (1975).
21. Fischer W.: Seizure 11, 285 (2002).
22. Porter R.J., Cereghino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.G.: Cleve. Clin. Q. 51, 293 (1984).
23. Porter R.J., Hessie B.J., Cereghino J.J., Gladding G.D., Kupferberg H.J., Scoville B., White B.G.: Fed. Proc. 44, 2645 (1985).